PEspeaks

May 08, 2012
Pharmaceutical Executive
Social networks existed long before Mark Zuckerberg came along. What hasn’t existed until recently are the tools, metrics and case studies necessary to understand how physicians influence each other within professional networks, and how these relationships can be used to change prescribing behavior.
May 07, 2012
Pharmaceutical Executive
The news that Roche scrapped development on its CETP inhibitor dalcetrapib, a drug designed to raise HDL cholesterol in the blood, likely presages the shuttering of Lilly’s development program for its CETP inhibitor, evacetrapib, industry experts and analysts sa
May 01, 2012
Pharmaceutical Executive
After almost nine years of working at Pharm Exec magazine, it’s time for me to move on.
May 01, 2012
Pharmaceutical Executive
If you really want to know what’s on a patient’s mind, it’s best to skip the small talk and go straight to the brain waves, as demonstrated by Neuro Insight CEO Pranav Yadav in the lead-off presentation yesterday at Chandler Chicco’s Pioneers in Digital Health conference.
Apr 27, 2012
Pharmaceutical Executive
While the FDA continues to develop its guidance for U.S. biosimilars, including a one-day public hearing on May 11, 2012, the basic legal underpinnings of biosimilars in the U.S. may be under threat, as the Supreme Court debates the healthcare law, a large chunk of which includes provisions for biosimilars.
Apr 26, 2012
Pharmaceutical Executive
I’ve been doing this digital thing for some time now. I’ve been part of and witnessed many changes in our digital world.
Apr 25, 2012
Pharmaceutical Executive
Last week Human Genome Sciences (HGS) rejected GlaxoSmithKline’s (GSK) unsolicited $2.59 billion bid for HGS or $13 per share.
Apr 25, 2012
Pharmaceutical Executive
Riding positive data on a late-phase multiple sclerosis drug, Genzyme execs talked up the company’s willingness to go head-to-head against Rebif, EMD Serono and Pfizer’s blockbuster beta interferon.
Apr 18, 2012
Pharmaceutical Executive
Chris Evans, West Pharmaceutical Services, and Ed Geiselhart, Insight Product Development, consider the importance of drug delivery systems in facilitating patient adherence.
Apr 18, 2012
Pharmaceutical Executive
The business outlook for pharma companies for the rest of 2012 and beyond is mixed, as pharma companies struggle to realign themselves to a new business model that will work.
native1_300x100
lorem ipsum